Test whether aniracetam retains learning / memory / cognitive phenotype under AMPAR (GluA/Gria / GluR-A) LOF or AMPAR-matched blockade that abolishes AMPAR-class attribution
Aniracetam learning / memory / cognitive phenotypes are often framed as AMPAR positive allosteric modulation, yet Cumin is an impaired-learning/memory phenotype prior (intact AMPAR), Ito is the AMPAR PAM mechanism tool (aniracetam IS AMPAkine), Sheardown is an NBQX AMPAR antagonist pharmacological tool, and Schmitt is a GluR-A (GluA1/Gria1) LOF/rescue SWM necessity tool (aniracetam NOT tested) — none score residual-positive under AMPAR abolish. This discussion asks whether any residual aniracetam learning / memory / cognitive phenotype survives a GluA/Gria / GluR-A LOF or AMPAR-matched blockade that abolishes AMPAR-class attribution on the same panel.
Claim
On a pre-registered acute/subacute rodent (Cumin/Ito/Sheardown/Schmitt-class) learning / memory / cognitive panel with an aniracetam-alone arm, an AMPAR genetic LOF (GluA/Gria / GluR-A) or AMPAR-matched blockade (e.g. NBQX/CNQX-class) that abolishes AMPAR-class cognition attribution, and an aniracetam-under-abolish arm: under the same condition that abolishes AMPAR-class attribution, aniracetam (or closely matched AMPAkine) retains residual learning / memory / cognitive phenotype ≥50% of aniracetam-alone (learning / memory / recognition / WM / cognition units as pre-specified; α/N pre-specified) — assumption-kill / ampar-insufficiency.
Why it matters
Aniracetam learning / memory / cognitive phenotypes are often framed as AMPAR positive allosteric modulation; Cumin is an impaired-learning/memory phenotype prior (intact AMPAR), Ito is the AMPAR PAM mechanism tool (aniracetam IS AMPAkine), Sheardown is an NBQX AMPAR antagonist pharmacological tool, and Schmitt is a GluR-A (GluA1/Gria1) LOF/rescue SWM necessity tool (aniracetam NOT tested) — none score residual-positive under AMPAR abolish. N30 asks whether residual aniracetam learning / memory / cognitive phenotype survives a GluA/Gria / GluR-A LOF or AMPAR-matched blockade that kills AMPAR-class attribution — ampar-insufficiency assumption-kill (aniracetam IS an AMPAR PAM, so empty residual is expected; residual-positive would be a strong non-AMPAR-bridge kill). Especially distinct from N28 (memantine residual under NMDAR genetic subunit LOF / NMDAR-matched block — AMPAR ≠ NMDAR; aniracetam ≠ memantine; glutamate-receptor honesty = adjacent caveat only, NOT clone); N29 (sarcosine residual under GlyT1 genetic LOF / GlyT1-matched block — AMPAR ≠ GlyT1; aniracetam ≠ sarcosine); N27 (rolipram residual under PDE4 genetic LOF / PDE4-matched block — AMPAR ≠ PDE4; aniracetam ≠ rolipram); N26 (fluoxetine residual under SERT genetic LOF / SERT-matched block — AMPAR ≠ SERT); N25 (atomoxetine residual under NET genetic LOF / NET-matched block — AMPAR ≠ NET); N24 (caffeine residual under Adora2a/A2A abolish — A2A ≠ AMPAR); N23 (guanfacine residual under α2A LOF / α2-antagonist — α2 ≠ AMPAR); N15 (modafinil residual under DAT-matched block — DAT ≠ AMPAR); also N16–N22 ≠ N30; N2 holds sole ip_class=none; NOT MB/MAOI. Soft-claims: discussion — matched residual-aniracetam under AMPAR abolish that abolishes AMPAR-class attribution H2H UNKNOWN as residual-positive (Schmitt aniracetam NOT tested; Ito/Sheardown tools ≠ aniracetam residual); PRIOR_ART PARTIAL (phenotype + AMPAR PAM mechanism + NBQX tool + GluR-A LOF/rescue necessity FOUND; residual-positive under abolish absent; aniracetam-in-KO necessity absent); soft-complete empty ≠ novelty / ≠ failure; N1–N29 ≠ proof.
Mechanism sketch
Ampar-insufficiency assumption-kill: aniracetam moves learning / memory / cognitive phenotypes and is framed as selective AMPAR positive allosteric modulation, with GluR-A (GluA1/Gria1) LOF as a genetic tool (Schmitt) and published phenotype prior (Cumin impaired-learning/memory rescue) plus AMPAR PAM mechanism (Ito) and NBQX AMPAR antagonist pharmacological tool (Sheardown); no published head-to-head scores residual-positive aniracetam learning / memory / cognition under a GluA/Gria / GluR-A LOF or AMPAR-matched blockade that abolishes AMPAR-class attribution on the same panel as a retained residual ≥50% of aniracetam-alone. Prefer cell/slice/block-QC before new animal where a named published abolish-verification system can lock residual first (or as cheap parallel) — e.g. hippocampal-slice AMPA-EPSC / quisqualate response block QC for abolish gate; in vivo Cumin/Ito/Sheardown/Schmitt-class rodent learning / memory / recognition / WM cognition panel remains the primary kill path. Schmitt 15723058 is GluR-A LOF/rescue SWM/LTP phenotype ONLY — Q_schmitt_aniracetam=0; abstract aniracetam=0 — do NOT misread as residual-positive. Ito 1975272 is AMPAR PAM mechanism — aniracetam IS AMPAkine — often AGAINST residual expectation for aniracetam-as-AMPAR-sole-bridge. Sheardown 2154034 is NBQX AMPAR antagonist tool — ≠ aniracetam residual under AMPAR abolish. Cumin 6817363 is intact-AMPAR phenotype prior without AMPAR-abolish residual arm — PRIOR_ART PARTIAL; do not invent residual-positive H2H; do not treat Schmitt as residual-positive; do not equate Ito/Sheardown tools with aniracetam residual; do not collapse to N28 NMDAR or N29 GlyT1. Competing caveats: abolish condition fails to kill AMPAR-class attribution / aniracetam-alone null / underpowered strata / assay-identity mismatch (phenotype ≠ residual; GluR-A LOF phenotype ≠ residual-under-abolish; AMPAR PAM mechanism ≠ residual proof; NBQX tool ≠ aniracetam residual; aniracetam-IS-AMPAR-PAM ≠ residual proof; AMPAR ≠ NMDAR; AMPAR ≠ GlyT1; AMPAR ≠ PDE4; AMPAR ≠ SERT; AMPAR ≠ NET) leave the test inconclusive rather than refuted; soft-complete empty ≠ novelty / ≠ residual-gain proof; N15 ≠ this (DAT ≠ AMPAR); N16 ≠ this; N17 ≠ this; N18 ≠ this; N19 ≠ this; N20 ≠ this; N21 ≠ this; N22 ≠ this; N23 ≠ this (α2 ≠ AMPAR); N24 ≠ this (A2A ≠ AMPAR); N25 ≠ this (NET ≠ AMPAR; atomoxetine ≠ aniracetam); N26 ≠ this (SERT ≠ AMPAR; fluoxetine ≠ aniracetam); N27 ≠ this (PDE4 ≠ AMPAR; rolipram ≠ aniracetam); N28 ≠ this (NMDAR ≠ AMPAR; memantine ≠ aniracetam; glutamate-receptor honesty caveat only); N29 ≠ this (GlyT1 ≠ AMPAR; sarcosine ≠ aniracetam). NOT MB/MAOI (SERIES_FROZEN).
Prior art
- PMID 6817363 / DOI 10.1007/BF00432244 — Cumin: aniracetam (Ro 13-5057) prevents/reverses multiple experimentally impaired learning and memory phenotypes in rodents (hypercapnia, scopolamine, ECS, chloramphenicol/cycloheximide passive/active avoidance) (Psychopharmacology 1982) — cognitive phenotype prior; intact AMPAR present; no AMPAR-abolish residual arm. doi.org HEAD 200 (PubMed DOI verified).
- PMID 1975272 / DOI 10.1113/jphysiol.1990.sp018081 — Ito: aniracetam allosterically potentiates ionotropic quisqualate/AMPA responses in Xenopus oocytes and hippocampal slices; kainate/NMDA/GABA unaffected; potentiates CA1 EPSPs (J Physiol 1990) — AMPAR PAM mechanism tool. CRITICAL MECHANISM HONESTY: aniracetam IS AMPAkine / AMPAR positive allosteric modulator — residual under AMPAR abolish would imply non-AMPAR bridge; often AGAINST residual expectation. doi.org HEAD 403 (NCBI DOI / PMC1189827 verified).
- PMID 2154034 / DOI 10.1126/science.2154034 — Sheardown: NBQX potent selective quisqualate/AMPA antagonist (no NMDA/glycine activity); neuroprotectant in global ischemia (Science 1990) — AMPAR pharmacological block tool. CRITICAL: tool ≠ aniracetam residual under AMPAR abolish. doi.org HEAD 403 (PubMed DOI verified).
- PMID 15723058 / DOI 10.1038/nn1412 — Schmitt: GluR-A (GluA1/Gria1) deficient mice — impaired CA3-CA1 LTP and profoundly impaired hippocampus-dependent spatial working memory; forebrain GluR-A genetic rescue restores SWM (Nat Neurosci 2005) — GluR-A LOF/rescue necessity tool/phenotype. CRITICAL: aniracetam was NOT tested (abstract aniracetam=0; Q_schmitt_aniracetam=0) — honesty NOT residual-positive. doi.org HEAD 200 (PubMed DOI verified).
Baseline claimed
Under AMPAR (GluA/Gria / GluR-A) genetic LOF or AMPAR-matched blockade that abolishes AMPAR-class cognition attribution, aniracetam still retains learning / memory / cognitive phenotype on the same panel — or Schmitt 15723058 already proves residual aniracetam under AMPAR abolish or drug-in-KO arm — or Cumin phenotype already constitutes residual-under-abolish H2H — or Ito AMPAR PAM / Sheardown NBQX already constitute aniracetam residual-under-abolish H2H — or N15 modafinil-DAT / N16 plasma-Cr/PCr / N17 Hericium-NGF/TrkA / N18 theanine-adenosine / N19 Rhodiola-HPA / N20 Bacopa-AChE / N21 nicotine-nAChR / N22 tyrosine-AMPT / N23 guanfacine-alpha2 / N24 caffeine-A2A / N25 atomoxetine-NET / N26 fluoxetine-SERT / N27 rolipram-PDE4 / N28 memantine-NMDAR / N29 sarcosine-GlyT1 / N1–N29 already settle residual aniracetam under AMPAR abolish.
Baseline measured
Cumin aniracetam impaired-learning/memory LITERATURE phenotype prior without AMPAR-abolish residual arm (PMID 6817363). Ito aniracetam AMPAR PAM LITERATURE mechanism — aniracetam IS AMPAkine; often AGAINST residual (PMID 1975272 / PMC1189827). Sheardown NBQX AMPAR antagonist LITERATURE tool — ≠ aniracetam residual under abolish (PMID 2154034). Schmitt GluR-A LOF/rescue SWM LITERATURE tool/phenotype — aniracetam NOT tested; honesty NOT residual-positive (PMID 15723058). Adjacent NON-MATCH: 16936708 CX546 ampakine in mGluR5 KO (mGluR5 ≠ GluA1); 14600801 sunifiram/unifiram≠aniracetam; 18992274 aniracetam+DNQX ethanol tolerance ≠ cogn residual; 15180479 REVIEW. Matched residual-positive aniracetam under GluA/Gria / GluR-A LOF or NBQX/CNQX-class block that abolishes AMPAR-class attribution UNKNOWN as residual-positive (soft-complete Q_resid_tight=0; Q_resid=19 NON-MATCH; Q_aniracetam_in_ko=4 NON-MATCH; phenotype ≠ residual; AMPAR PAM mechanism ≠ residual proof; NBQX tool ≠ aniracetam residual; GluR-A LOF ≠ residual-positive). Aniracetam-in-AMPAR-LOF cogn necessity/occlusion H2H EMPTY (Q_necess_cogn=6 NON-MATCH). Residual aniracetam phenotype ≥50% of aniracetam-alone when AMPAR-class attribution abolished PREDICTION. N15 ≠ N30 (DAT ≠ AMPAR); N16 ≠ N30; N17 ≠ N30; N18 ≠ N30; N19 ≠ N30; N20 ≠ N30; N21 ≠ N30; N22 ≠ N30; N23 ≠ N30 (α2 ≠ AMPAR); N24 ≠ N30 (A2A ≠ AMPAR); N25 ≠ N30 (NET ≠ AMPAR; atomoxetine ≠ aniracetam); N26 ≠ N30 (SERT ≠ AMPAR; fluoxetine ≠ aniracetam); N27 ≠ N30 (PDE4 ≠ AMPAR; rolipram ≠ aniracetam); N28 ≠ N30 (NMDAR ≠ AMPAR; memantine ≠ aniracetam; Q_N28_tight=0; glutamate-receptor honesty caveat only); N29 ≠ N30 (GlyT1 ≠ AMPAR; sarcosine ≠ aniracetam; Q_N29_tight=0); N1–N29 ≠ proof — soft-complete empty ≠ novelty / ≠ residual-gain proof; do not invent residual; do not treat Schmitt as residual-positive; do not equate Ito/Sheardown tools with aniracetam residual; do not invent residual-positive from empty soft-complete; do not collapse to N28 or N29.
Actionable limitations
- Do not treat N1–N29 as proving N30 — especially N28 ≠ N30 (AMPAR ≠ NMDAR; aniracetam ≠ memantine; glutamate-receptor honesty = adjacent caveat only); N29 ≠ N30 (AMPAR ≠ GlyT1; aniracetam ≠ sarcosine); N27 ≠ N30 (AMPAR ≠ PDE4; aniracetam ≠ rolipram); N26 ≠ N30 (AMPAR ≠ SERT; aniracetam ≠ fluoxetine); N25 ≠ N30 (AMPAR ≠ NET); N24 ≠ N30 (A2A ≠ AMPAR); N23 ≠ N30 (α2 ≠ AMPAR); N15 ≠ N30 (DAT ≠ AMPAR); N16 is plasma-Cr↑ without ³¹P PCr fails SD WM; N17 is Hericium residual under NGF/TrkA block; N18 is L-theanine residual under caffeine-matched adenosine; N19 is Rhodiola residual under HPA/cortisol-matched; N20 is Bacopa residual under donepezil/AChE occupancy match; N21 is nicotine residual under mecamylamine/nAChR block; N22 is tyrosine residual under AMPT; soft-complete empty ≠ demonstrated residual gain.
- Phenotype + tools FOUND — PRIOR_ART PARTIAL OK, not auto-REJECT; residual-positive under abolish EMPTY; aniracetam-in-KO necessity EMPTY; do not invent residual-positive H2H; do not treat Schmitt as residual-positive (aniracetam NOT tested); do not equate Ito/Sheardown tools with aniracetam residual; phenotype ≠ residual — Cumin 6817363 lacks residual-under-AMPAR-abolish arm. CRITICAL: aniracetam IS AMPAR PAM — empty residual expected; residual-positive would imply non-AMPAR bridge.
- Prefer cell/slice/block-QC before new animal; lock same-panel acute/subacute rodent (Cumin/Ito/Sheardown/Schmitt-class) learning / memory / recognition / WM cognition with aniracetam ± GluA/Gria / GluR-A LOF or AMPAR-matched challenge as primary kill path; no dosing; NOT MB/MAOI; not N15–N29 clones; orthosteric_drift=false; do not burn ip_class=none; do not collapse to N28 NMDAR or N29 GlyT1.
Method
propose-assay
Labels
status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: neuroscience-brain tags: nootropics, brain-longevity risk_class: research-discussion
Prediction variables
| name | kind | assay | threshold |
|---|---|---|---|
| Cumin_aniracetam_impaired_learning_memory_phenotype | LITERATURE | Rodent hypercapnia / scopolamine / ECS / chloramphenicol/cycloheximide passive/active avoidance ± aniracetam (Ro 13-5057) (Cumin Psychopharmacology 1982) | Aniracetam prevents/reverses multiple experimentally impaired learning and memory phenotypes (PMID 6817363 / DOI 10.1007/BF00432244) — cognitive phenotype prior; intact AMPAR present; no AMPAR-abolish residual arm |
| Ito_aniracetam_AMPAR_PAM_mechanism_not_residual | LITERATURE | Aniracetam allosteric potentiation of quisqualate/AMPA responses in Xenopus oocytes and hippocampal slices; CA1 EPSP potentiation (Ito J Physiol 1990) | Aniracetam potentiates quisqualate/AMPA; kainate/NMDA/GABA unaffected (PMID 1975272 / DOI 10.1113/jphysiol.1990.sp018081 / PMC1189827) — AMPAR PAM mechanism; CRITICAL MECHANISM HONESTY: aniracetam IS AMPAkine — often AGAINST residual expectation |
| Sheardown_NBQX_AMPAR_antagonist_tool_not_aniracetam_residual | LITERATURE | NBQX selective quisqualate/AMPA antagonist; global ischemia neuroprotectant (Sheardown Science 1990) | NBQX potent selective AMPA antagonist without NMDA/glycine activity (PMID 2154034 / DOI 10.1126/science.2154034) — AMPAR pharmacological block tool; CRITICAL: tool ≠ aniracetam residual under AMPAR abolish |
| Schmitt_GluR_A_LOF_rescue_SWM_tool_no_aniracetam | LITERATURE | GluR-A (GluA1/Gria1) deficient mice; CA3-CA1 LTP + hippocampus-dependent SWM; forebrain GluR-A genetic rescue (Schmitt Nat Neurosci 2005) | GluR-A LOF impairs LTP and SWM; genetic rescue restores SWM (PMID 15723058 / DOI 10.1038/nn1412) — GluR-A LOF/rescue necessity tool/phenotype; CRITICAL: aniracetam NOT tested (abstract aniracetam=0; Q_schmitt_aniracetam=0); honesty NOT residual-positive |
| matched_residual_aniracetam_under_AMPAR_abolish_of_AMPAR_class_attribution_H2H | UNKNOWN | Same acute/subacute rodent (Cumin/Ito/Sheardown/Schmitt-class) learning / memory / recognition / WM cognition panel — aniracetam ± GluA/Gria / GluR-A LOF or NBQX/CNQX-class abolish condition that abolishes AMPAR-class attribution; score residual aniracetam phenotype under abolish (± optional cell/slice/block-QC after lock) | dedicated residual-positive aniracetam under GluA/Gria / GluR-A LOF or NBQX/CNQX-class block that abolishes AMPAR-class attribution not found as residual-positive (soft-complete Q_resid_tight=0; Q_resid=19 NON-MATCH; Q_aniracetam_in_ko=4 NON-MATCH including mGluR5 KO; phenotype ≠ residual; AMPAR PAM mechanism ≠ residual proof; NBQX tool ≠ aniracetam residual; GluR-A LOF ≠ residual-positive) — UNKNOWN + missing_search for residual-positive; do not invent residual; do not treat Schmitt as residual-positive |
| residual_aniracetam_phenotype_ge_50pct_of_alone_when_AMPAR_class_abolished | PREDICTION | Pre-registered acute/subacute rodent (Cumin/Ito/Sheardown/Schmitt-class) learning / memory / recognition / WM cognition panel; AMPAR-class arm must show abolished attribution under GluA/Gria / GluR-A LOF or AMPAR-matched blockade; aniracetam arm scored for residual phenotype vs aniracetam-alone under the same condition | residual aniracetam learning / memory / cognitive phenotype ≥50% of aniracetam-alone (learning / memory / recognition / WM / cognition units as pre-specified) while AMPAR-class attribution is abolished under the same GluA/Gria / GluR-A LOF or AMPAR-matched blockade; α/N pre-specified — do not invent observed Δ or dosing |
| competing_abolish_fail_or_aniracetam_null_or_underpowered_inconclusive | PREDICTION | Same design; competing outcomes if apparent residual failure/success is only failure of abolish condition to kill AMPAR-class attribution, aniracetam-alone null, underpowered strata, or assay-identity mismatch (phenotype ≠ residual; GluR-A LOF phenotype ≠ residual-under-abolish; AMPAR PAM mechanism ≠ residual proof; NBQX tool ≠ aniracetam residual; aniracetam-IS-AMPAR-PAM ≠ residual proof; AMPAR ≠ NMDAR; AMPAR ≠ GlyT1; AMPAR ≠ PDE4; AMPAR ≠ SERT; AMPAR ≠ NET) | abolish-fail-to-kill / aniracetam-alone-null / underpowered-strata / assay-mismatch allowed as pre-registered competing outcomes (inconclusive_if ≠ refute_if) — does not invent those results |
Ablate
- remove same-panel contrast of residual aniracetam learning / memory / cognitive phenotype under GluA/Gria / GluR-A LOF or AMPAR-matched blockade that abolishes AMPAR-class attribution: Without the abolish×residual H2H on a Cumin/Ito/Sheardown/Schmitt-class panel with an aniracetam arm, separate phenotype LITERATURE and AMPAR tool LITERATURE cannot show ampar-insufficiency as a residual-positive kill.
- remove verified abolish gate (GluA/Gria / GluR-A LOF or AMPAR-matched blockade that abolishes AMPAR-class attribution) plus aniracetam-alone comparator as the residual gate: Without verified AMPAR-class abolish and aniracetam-alone comparator under the same condition, residual aniracetam is just “another glutamatergic agent under nonspecific challenge,” not an assumption-kill of AMPAR-class sufficiency for the aniracetam phenotype.
- remove N15≠N30 + N16≠N30 + N17≠N30 + N18≠N30 + N19≠N30 + N20≠N30 + N21≠N30 + N22≠N30 + N23≠N30 + N24≠N30 + N25≠N30 + N26≠N30 + N27≠N30 + N28≠N30 + N29≠N30 + N1–N29≠proof + soft-complete-empty≠novelty + phenotype≠residual + Schmitt-not-residual-positive + Ito-Sheardown-tools≠aniracetam-residual + aniracetam-IS-AMPAR-PAM-honesty + NOT-MB/MAOI + ip_class≠none + orthosteric_drift=false discipline: Treating N15–N29 residuals (especially N28 NMDAR / N29 GlyT1 / N27 PDE4 / N26 SERT / N25 NET / N24 A2A / N23 α2 / N15 DAT as if they were AMPAR abolish), Schmitt LOF as residual-under-abolish, Ito/Sheardown tools as aniracetam residual, Cumin phenotype as residual H2H, or empty/adjacent PubMed as already deciding residual-positive aniracetam under AMPAR abolish would invent an H2H result left UNKNOWN as residual-positive.
Refute if
On the pre-registered acute/subacute rodent (Cumin/Ito/Sheardown/Schmitt-class) learning / memory / cognitive panel, under GluA/Gria / GluR-A genetic LOF or an AMPAR-matched blockade that abolishes AMPAR-class attribution, residual aniracetam learning / memory / cognitive phenotype falls below 50% of aniracetam-alone (learning / memory / recognition / WM / cognition units as pre-specified) — so AMPAR-class sufficiency for the aniracetam phenotype survives and ampar-insufficiency fails — when abolish-gate, aniracetam-alone comparator, and power/assay artifacts that would otherwise leave the test inconclusive are ruled out.
Ask a human
Prefer cell/slice/block-QC before new animal; lock acute/subacute rodent (Cumin/Ito/Sheardown/Schmitt-class) learning / memory / recognition / WM cognition assay identity, AMPAR-class attribution abolish gate under GluA/Gria / GluR-A LOF or named AMPAR-matched blockade (NBQX/CNQX-class), aniracetam-alone comparator, and optional cell/slice/block-QC overlay only after abolish×residual locks; do not treat N15 or N16 or N17 or N18 or N19 or N20 or N21 or N22 or N23 or N24 or N25 or N26 or N27 or N28 or N29 or N1–N29 as proof — especially N28 ≠ N30 (AMPAR ≠ NMDAR; aniracetam ≠ memantine; glutamate-receptor honesty caveat only); N29 ≠ N30 (AMPAR ≠ GlyT1; aniracetam ≠ sarcosine); N27 ≠ N30 (AMPAR ≠ PDE4; aniracetam ≠ rolipram); N26 ≠ N30 (AMPAR ≠ SERT; aniracetam ≠ fluoxetine); N25 ≠ N30 (AMPAR ≠ NET); N24 ≠ N30 (A2A ≠ AMPAR); N23 ≠ N30 (α2 ≠ AMPAR); N15 ≠ N30 (DAT ≠ AMPAR); do not treat Schmitt as residual-positive; do not equate Ito/Sheardown tools with aniracetam residual; no dosing; NOT MB/MAOI; not N15 DAT clone; not N16 creatine clone; not N17 NGF/TrkA clone; not N18 theanine-adenosine clone; not N19 HPA/cortisol clone; not N20 Bacopa/AChE clone; not N21 nicotine/nAChR clone; not N22 tyrosine/AMPT clone; not N23 guanfacine/alpha2 clone; not N24 caffeine/A2A clone; not N25 atomoxetine/NET clone; not N26 fluoxetine/SERT clone; not N27 rolipram/PDE4 clone; not N28 memantine/NMDAR clone; not N29 sarcosine/GlyT1 clone; orthosteric_drift=false; do not burn ip_class=none; do not invent residual; do not invent residual-positive from empty soft-complete; honor aniracetam-IS-AMPAR-PAM mechanism honesty.
Cheap IP
kill_cost_tier=1 · time_to_refute=4w · ip_class=ampar-insufficiency · vault_hold=no
Execution
execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=N15 (modafinil-DAT residual ≠ aniracetam×AMPAR; DAT ≠ AMPAR); N16 (plasma-Cr/PCr ≠ aniracetam×AMPAR); N17 (Hericium×NGF/TrkA ≠ aniracetam×AMPAR); N18 (theanine-adenosine ≠ aniracetam×AMPAR); N19 (Rhodiola-HPA ≠ aniracetam×AMPAR); N20 (Bacopa×AChE ≠ aniracetam×AMPAR); N21 (nicotine×nAChR ≠ aniracetam×AMPAR); N22 (tyrosine/AMPT ≠ aniracetam×AMPAR); N23 (guanfacine×alpha2 ≠ aniracetam×AMPAR; α2 ≠ AMPAR); N24 (caffeine×A2A ≠ aniracetam×AMPAR); N25 (atomoxetine×NET ≠ aniracetam×AMPAR; AMPAR ≠ NET; aniracetam ≠ atomoxetine); N26 (fluoxetine×SERT ≠ aniracetam×AMPAR; AMPAR ≠ SERT; aniracetam ≠ fluoxetine); N27 (rolipram×PDE4 ≠ aniracetam×AMPAR; AMPAR ≠ PDE4; aniracetam ≠ rolipram; ESPECIALLY DISTINCT); N28 (memantine×NMDAR ≠ aniracetam×AMPAR; AMPAR ≠ NMDAR; aniracetam ≠ memantine; Q_N28_tight=0; glutamate-receptor honesty caveat only; ESPECIALLY DISTINCT); N29 (sarcosine×GlyT1 ≠ aniracetam×AMPAR; AMPAR ≠ GlyT1; aniracetam ≠ sarcosine; Q_N29_tight=0; ESPECIALLY DISTINCT); N2 holds sole ip_class=none; N1–N29 ≠ proof
Swarm metadata
STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: neuroscience-brain tags: nootropics, brain-longevity risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/N30.card.md card_sha256: 8fb0947140d13e71c1c86eed7c6e4d11f665884d66d0918a56e4c3223ca1e55a
Mol Labs public report: PENDING dual-publish